Cyrano Therapeutics

Ignite Your
Senses,
Rediscover
Scent

The first pharmaceutical therapy
for smell and flavor loss.

At Cyrano Therapeutics, we’re dedicated to developing a therapy for people dealing with long-term smell and flavor loss. This condition was estimated to affect over 15 million people in the US alone before the COVID-19 pandemic, 4 million of whom had lost their smell due to a flu virus. Since the pandemic, the number of patients with long-term smell loss from a virus has increased more than 10 fold, with thousands of new patients emerging each day.
Therapy for Smell and Flavor Loss

Since the pandemic, the number of patients with long-term smell loss due to a virus has increased 10 fold to more than 40 million patients in the US and Europe.1-4

Restore Your Senses | Smell and Flavor Loss Therapy | Cyrano Therapeutics

Learn more about sensory dysfunction

Reverse Sensory Dysfunction

Olfactory System Explained

Sensory Dysfunction Repair

Sensory Dysfunction Statistics

Repairing Sense of Smell

Safety & Social Implications

Restore Your Senses | Smell and Flavor Loss Therapy | Cyrano Therapeutics

References: 1. Coelho DH, Reiter ER, French E, Costanzo RM. Decreasing Incidence of Chemosensory Changes by COVID-19 Variant [published online ahead of print, 2022 May 3]. Otolaryngol Head Neck Surg. 2022;1945998221097656. doi:10.1177/01945998221097656. 2. Saniasiaya J, Islam MA, Abdullah B. Prevalence and Characteristics of Taste Disorders in Cases of COVID-19: A Meta-analysis of 29,349 Patients. Otolaryngol Head Neck Surg. 2021;165(1):33-42. doi:10.1177/0194599820981018 3. Boscolo-Rizzo P, Hummel T, Hopkins C, et al. High prevalence of long-term olfactory, gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation. Rhinology. 2021;59(6):517-527. doi:10.4193/Rhin21.249 4. Boscolo-Rizzo P, Guida F, Polesel J, et al. Self-reported smell and taste recovery in coronavirus disease 2019 patients: a one-year prospective study. Eur Arch Otorhinolaryngol. 2022;279(1):515-520. doi:10.1007/s00405-021-06839-w